Articles
Executive perspectives: John Castellani

Executive perspectives: John Castellani

With the US pharma market also feeling the winds of change, Paul Tunnah speaks with PhRMA CEO John Castellani to hear his views on the future for the industry. As one of the most influential figures in pharma it is notable that Castellani is a relative newcomer to the sector, having taken the lead role at The Pharmaceutical Research…

Articles
Coming soon – pharmacogenomics

Coming soon – pharmacogenomics

Daniella Koren explores the possibilities that pharmacogenomics is opening up for us. What would have once sounded like the plot of a ’50s sci-fi novel is the near future of medicine —medications will be...

Articles
Pharma gets social – social media brings Millennium: The Takeda Oncology Company closer to people

Pharma gets social – social media brings Millennium: The Tak...

Daniel Ghinn’s latest monthly article looks at the use of social media by Milllenium: The Takeda Oncology Company to add value in a niche disease area, such as rare diseases. Over recent months I have compared how selected channels are being used by the world’s largest pharmaceutical companies, with reviews of...

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D